1. In Vivo
  2. >>Global Vision

Igeneon: Staying Close to Home

 
• By Chris Morrison

Igeneon's latest in-licensing rounds out its cancer immunotherapy pipeline with another compound its founders know well. IGN 301, an epithelial cancer vaccine, is the second of Igeneon's three clinical projects to originate from Novartis. Both were discovered under the guidance of Igeneon's founders, who have a combined 50 years' experience at the Swiss giant.

igeneon AG , a Vienna-based biotech company developing active and passive immunotherapies to treat cancer, was created with Novartis AG 's Phase I epithelial cancer vaccine in mind. The therapeutic candidate—based on an antibody that provokes an immune response to Lewis Y, a sugar expressed on the surface of lung, intestinal, breast, prostate and ovarian cancers—was discovered in the lab of Hans Loibner, PhD, founder and CEO of Igeneon. Loibner had previously spent more than 20 years in various R&D positions at Sandoz, which merged with Ciba-Geigy in 1996 to create Novartis [See Deal].

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Global Vision

Barcelona’s S2 Xpeed Accelerates Hardware-Based Medtech Start-Ups From Prototype To Market

 
• By Marion Webb

S2 Xpeed is driving the rapid growth of medtech and hardware start-ups in Europe. Operating under a "sweat equity" model, the program helps early-stage companies move from prototype to manufacturing readiness in exchange for equity.

Rising Leaders 2025: Partnerships Propel Crystal Qin’s LaNova To Record-Breaking Merck Deal

 
• By Brian Yang

Crystal Qin has led LaNova Medicines’ swift rise in the biotech world through strategic partnerships and innovative R&D, highlighted by a record deal with big pharma.

Barcelona Health Hub: Where Digital Health Innovation Meets Historic Art Nouveau

 
• By Marion Webb

The Barcelona Health Hub is a nonprofit that seeks to advance digital health innovation by bringing together start-ups, investors, health care institutions and corporations.

Reinventing Prevention: Milken Institute Foresees Another Route Using Private And Public Funding

 
• By Ashley Yeo

New funding mechanisms are required to give more momentum to prevention in the community and thereby relieve pressure on overburdened health care providers like the UK National Health Service. So says Simon Radford, a director at global thinktank the Milken Institute, which sees a solution in more funding for community-level prevention.

More from In Vivo

Building The Worm Atlas For I&I Breakthroughs

 
• By Ian Taylor

The next big thing in auto-immune therapies: worms. Or so a young California biotech believes. Holoclara is pioneering a new class of medicines derived from intestinal worms to revolutionize the treatment of autoimmune diseases, allergies, and more.

Reforming The Rx Rulers: A New Script For PBMs

 
• By Andrew Cox

As PBMs shift to value-based contracts, federal and state efforts seek to reduce drug costs, increase transparency and tackle anticompetitive practices.

Podcast: OSE Immunotherapeutics’ CEO On Ulcerative Colitis Asset

 
• By David Wild

Nicolas Poirier, CEO of French biotech OSE Immunotherapeutics, spoke with In Vivo about the company's anti-IL-7R antibody, lusvertikimab, on the heels of impressive ulcerative colitis data presented at the 2025 European Crohn's and Colitis Organization meeting.